Loading...
Kymera Therapeutics, Inc.
KYMR•NASDAQ
Healthcare
Biotechnology
$45.79
$-0.06(-0.13%)
Kymera Therapeutics, Inc. (KYMR) Financial Performance & Income Statement Overview
Review Kymera Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-40.11%
↓ 40.11%
Operating Income Growth
-58.06%
↓ 58.06%
Net Income Growth
-52.32%
↓ 52.32%
Operating Cash Flow Growth
-89.16%
↓ 89.16%
Operating Margin
-472.50%
↓ 472.50%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-409.07%
↓ 409.07%
ROE
-30.11%
↓ 30.11%
ROIC
-32.38%
↓ 32.38%
Kymera Therapeutics, Inc. (KYMR) Income Statement & Financial Overview
Review Kymera Therapeutics, Inc.'s (KYMR) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.39M | $3.74M | $25.65M | $10.29M |
| Cost of Revenue | $1.97M | $2.00M | $1.90M | $1.50M |
| Gross Profit | $5.42M | $1.74M | $23.75M | $8.79M |
| Gross Profit Ratio | $0.73 | $0.47 | $0.93 | $0.85 |
| R&D Expenses | $69.84M | $60.41M | $57.30M | $48.82M |
| SG&A Expenses | $16.33M | $15.46M | $17.37M | $14.37M |
| Operating Expenses | $88.15M | $75.86M | $74.67M | $61.69M |
| Total Costs & Expenses | $88.15M | $75.86M | $76.58M | $63.19M |
| Interest Income | $10.06M | $9.70M | $8.92M | $9.34M |
| Interest Expense | $59000.00 | $60000.00 | $61000.00 | $69000.00 |
| Depreciation & Amortization | $1.97M | $2.00M | $1.90M | $1.50M |
| EBITDA | -$68.72M | -$60.43M | -$40.10M | -$46.99M |
| EBITDA Ratio | -$9.29 | -$16.15 | -$1.56 | -$4.57 |
| Operating Income | -$80.75M | -$72.12M | -$50.92M | -$52.91M |
| Operating Income Ratio | -$10.92 | -$19.28 | -$1.99 | -$5.14 |
| Other Income/Expenses (Net) | $10.003M | $9.64M | $8.86M | $4.35M |
| Income Before Tax | -$70.75M | -$62.49M | -$42.06M | -$48.56M |
| Income Before Tax Ratio | -$9.57 | -$16.70 | -$1.64 | -$4.72 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $39000.00 |
| Net Income | -$70.75M | -$62.49M | -$42.06M | -$48.56M |
| Net Income Ratio | -$9.57 | -$16.70 | -$1.64 | -$4.72 |
| EPS | -$0.88 | -$0.82 | -$0.58 | -$0.69 |
| Diluted EPS | -$0.88 | -$0.82 | -$0.58 | -$0.69 |
| Weighted Avg Shares Outstanding | $79.99M | $76.13M | $73.06M | $70.77M |
| Weighted Avg Shares Outstanding (Diluted) | $79.99M | $76.13M | $73.06M | $70.77M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan